Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 6 |
| List of Tables | 6 | 1 |
| List of Figures | 7 | 1 |
| Introduction | 8 | 1 |
| Global Markets Direct Report Coverage | 8 | 1 |
| Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Overview | 9 | 1 |
| Therapeutics Development | 10 | 1 |
| Pipeline Products for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Overview | 10 | 1 |
| Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Therapeutics under Development by Companies | 11 | 2 |
| Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Pipeline Products Glance | 13 | 3 |
| Late Stage Products | 13 | 1 |
| Clinical Stage Products | 14 | 1 |
| Early Stage Products | 15 | 1 |
| Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Products under Development by Companies | 16 | 2 |
| Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Companies Involved in Therapeutics Development | 18 | 19 |
| 3SBio Inc. | 18 | 1 |
| AkaRx Inc | 19 | 1 |
| Amgen Inc. | 20 | 1 |
| arGEN-X BV | 21 | 1 |
| Boehringer Ingelheim GmbH | 22 | 1 |
| Bristol-Myers Squibb Company | 23 | 1 |
| Genosco | 24 | 1 |
| Hansa Medical AB | 25 | 1 |
| Immunomedics, Inc. | 26 | 1 |
| Intas Pharmaceuticals Ltd. | 27 | 1 |
| Jiangsu Hengrui Medicine Co., Ltd. | 28 | 1 |
| Merck &Co., Inc. | 29 | 1 |
| Momenta Pharmaceuticals, Inc. | 30 | 1 |
| Novartis AG | 31 | 1 |
| Pfizer Inc. | 32 | 1 |
| PhytoHealth Corporation | 33 | 1 |
| Protalex, Inc. | 34 | 1 |
| Rigel Pharmaceuticals, Inc. | 35 | 1 |
| Shire Plc | 36 | 1 |
| Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Therapeutics Assessment | 37 | 9 |
| Assessment by Monotherapy Products | 37 | 1 |
| Assessment by Target | 38 | 2 |
| Assessment by Mechanism of Action | 40 | 2 |
| Assessment by Route of Administration | 42 | 2 |
| Assessment by Molecule Type | 44 | 2 |
| Drug Profiles | 46 | 48 |
| Antibody for Autoimmune Disorders and Inflammation Drug Profile | 46 | 1 |
| ARGX-113 Drug Profile | 47 | 2 |
| avatrombopag Drug Profile | 49 | 2 |
| BI-655064 Drug Profile | 51 | 2 |
| BMS-986004 Drug Profile | 53 | 1 |
| eltrombopag olamine Drug Profile | 54 | 6 |
| eltrombopag olamine Drug Profile | 60 | 1 |
| fostamatinib disodium Drug Profile | 61 | 5 |
| GL-2045 Drug Profile | 66 | 1 |
| GSK-2285921 Drug Profile | 67 | 2 |
| Hetrombopag Olamine Drug Profile | 69 | 1 |
| M-281 Drug Profile | 70 | 1 |
| MK-8723 Drug Profile | 71 | 1 |
| PHN-013 Drug Profile | 72 | 1 |
| PRTX-100 Drug Profile | 73 | 7 |
| Recombinant Enzyme to Inhibit Immunoglobulin G for Autoimmune Diseases Drug Profile | 80 | 1 |
| romiplostim Drug Profile | 81 | 3 |
| romiplostim biosimilar Drug Profile | 84 | 1 |
| SKIO-703 Drug Profile | 85 | 1 |
| SM-101 Drug Profile | 86 | 3 |
| thrombopoietin Drug Profile | 89 | 1 |
| veltuzumab Drug Profile | 90 | 4 |
| Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Dormant Projects | 94 | 1 |
| Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Discontinued Products | 95 | 1 |
| Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Product Development Milestones | 96 | 11 |
| Featured News &Press Releases | 96 | 1 |
| Jun 10, 2016: Novartis highlights long-term safety data of Revolade in adults with chronic immune thrombocytopenia, a rare blood disorder | 96 | 1 |
| May 19, 2016: Amgen Highlights Data on Nplate (romiplostim) at 21st Congress Of The European Hematology Association | 97 | 1 |
| Apr 07, 2016: Novartis receives EU approval for Revolade as first-in-class therapy for children aged 1 year and above with chronic ITP | 98 | 1 |
| Apr 01, 2016: Rigel Completes Enrollment of FIT Phase 3 Program for Fostamatinib in ITP | 99 | 1 |
| Jan 29, 2016: CHMP adopts extension to existing therapeutic indication for eltrombopag | 100 | 1 |
| Jan 28, 2016: Rigel Completes Enrollment of First Phase 3 Study of Fostamatinib in ITP | 100 | 1 |
| Jan 07, 2016: Rigel Reviews Recent Progress and Announces Presentation at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco | 101 | 1 |
| Sep 08, 2015: Rigel Granted Orphan Drug Designation for Fostamatinib in ITP | 102 | 1 |
| Jun 11, 2015: Novartis gains FDA approval for Promacta providing new option for children, ages 6 and older, with chronic ITP, a rare blood disorder | 102 | 1 |
| Feb 06, 2015: GSK announces EU regulatory submission seeking additional indication for eltrombopag (Revolade) | 103 | 1 |
| Dec 22, 2014: GSK announces US regulatory submission seeking additional indication for eltrombopag (Promacta) | 104 | 1 |
| Jul 16, 2014: Rigel Initiates Phase 3 Studies of Fostamatinib in ITP | 104 | 1 |
| Oct 31, 2013: Kyowa Hakko Kirin Announces Launch Of Nplate In Taiwan | 105 | 1 |
| Oct 24, 2013: Rigel Provides Update On Oral SYK Inhibitor Fostamatinib | 105 | 1 |
| Jul 24, 2013: NICE says yes to blood disorder treatment in final guidance | 105 | 2 |
| Appendix | 107 | 2 |
| Methodology | 107 | 1 |
| Coverage | 107 | 1 |
| Secondary Research | 107 | 1 |
| Primary Research | 107 | 1 |
| Expert Panel Validation | 107 | 1 |
| Contact Us | 107 | 1 |
| Disclaimer | 108 | 1 |